Investment Newsletters

Agile

With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts?

H.C.

Julie Lamb — December 8, 2017, 7:58 AM EDT

Agile Initiated With A Buy At Janney Capital; Considers AGRX A Compelling Investment

Janney Capital analyst Kimberly Lee is out today with an interesting call initiating Agile Therapeutics, Inc. (AGRX) with a Buy rating and $18 fair …

Ben Mahaney, Editor — June 17, 2014, 4:16 PM EDT